DOCSLIB.ORG

Lactamase Producing Bacteria and Their Bacteriophages from Wastewater

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lactamase Producing Bacteria and Their Bacteriophages from Wastewater Characterization of novel extended spectrum beta- lactamase producing bacteria and their bacteriophages from wastewater by Nanpon Miri The thesis is submitted in partial fulfilment of the requirements for the award of the degree of DOCTOR OF PHILOSOPHY of the University of Portsmouth School of Pharmacy and Biomedical Sciences September 2020 i Abstract Multidrug-resistant bacteria strains possessing extended-spectrum β-lactamases (ESBLs) has become an increasing problem worldwide. Bacteria resistant to antibiotics are mostly enteric, they can contaminate the environment and, through ingestion, enter new hosts to cause infections. Therefore, emphasis was put on isolating ESBL-producing bacteria from treated wastewater. The overall aim of this thesis was to isolate, identify and characterise ESBL-producing bacteria from wastewater followed by isolation and characterisation of bacteriophages specific for these bacteria. Bacterial isolates were recovered after growth on selective media and multiplex PCR was used to amplify SHV, TEM, CTX-M and OXA genes. Biochemical test and whole genome sequencing were applied to identify and characterise the isolated strains. The cell-free supernatants were then used to isolate bacteriophages. A high titer lysate was then used to test the specificity of bacteriophages for different bacterial strains. The nature of phage genetic material was established and morphology of isolated phages was determined by the transmission electron microscopy imaging. Two cold-tolerant bacteria isolated harbouring CTX-M gene were studied by 16S rRNA gene sequence analysis and housekeeping gene sequences analysis which revealed that these isolates showed no close similarity to any known member of the Enterobacteriaceae but are related to the members of Rahnella, Rouxiella and Ewingella genera. The phenotypic characteristics of the two isolates were, however, discrete from these 3 genera. Furthermore, two different bacteriophages infected the two newly identified cold tolerant bacterial strains. These bacteriophages were found to be novel viruses, most likely belonging to the Siphoviridae family, based on their characteristics, morphology, and genome size. In conclusion, all the analysis showed that they two isolates belong to a novel genus in the Enterobacteriaceae family. Given the menacing impact of disease outbreaks caused by contaminated water resources, work presented here identifies novel bacteria with harmful capabilities and potentially offers new tools for environmentally safer treatment to overcome this threat. ii Declaration Whilst registered as a candidate for the above degree, I have not been registered for any other research award. The results and conclusions embodied in this thesis are the work of the named candidate and have not been submitted for any other academic award. Word Count: 30534 iii Table of Contents Abstract ............................................................................................................................................... ii Declaration ......................................................................................................................................... iii List of Figures .................................................................................................................................... vii List of Tables .................................................................................................................................... viii Acknowledgement .............................................................................................................................. ix List of Abbreviations ............................................................................................................................ x 1.0 Introduction ........................................................................................................................... 1 1.1 Wastewater treatment ....................................................................................................... 1 1.2 Enteric microorganisms present in wastewater ............................................................ 3 1.2.1 The Enterobacterales ................................................................................................ 3 1.2.2 Pseudomonadales .................................................................................................... 7 1.3 Antibiotics, β-lactam antibiotics, and mode of resistance ........................................... 7 1.3.1 Antibiotic resistance ................................................................................................. 9 1.3.2 β-lactamases ............................................................................................................ 11 1.3.3 Extended-spectrum β-lactamases ......................................................................... 12 1.3.4 Extended-spectrum β-lactamases in Rahnella and Ewingella ........................... 13 1.3.5 Virulence factors of extended-spectrum β-lactamases ...................................... 14 1.3.6 The rise of antibiotic resistance and importance of finding new treatments ... 15 1.4 Phage Biology and classification .................................................................................. 16 1.5 Phage Infection................................................................................................................ 17 1.6 Phage evolution............................................................................................................... 19 1.7 Bacterial defence system against phages .................................................................... 19 1.7.1 Adsorption inhibition .............................................................................................. 19 1.7.2 Restriction modification systems .......................................................................... 20 1.7.3 CRISPR-Cas ............................................................................................................. 21 1.7.4 Abortive infection .................................................................................................... 21 1.8 History of phages and phage therapy ........................................................................... 23 1.9 Mechanism of Phage Therapy ....................................................................................... 24 1.10 Statement of aims and objectives ................................................................................. 25 2.0 Materials and Methods ....................................................................................................... 26 2.1 Media preparation ........................................................................................................... 26 2.1.1 LB medium ............................................................................................................... 26 2.1.2 LB agar ..................................................................................................................... 26 2.1.3 Mueller-Hinton Agar ................................................................................................ 26 2.1.4 Tryptone soy broth ................................................................................................. 26 2.1.5 Tryptone soy agar ................................................................................................... 26 2.1.6 Soft agar ................................................................................................................... 27 2.1.7 Bacteriophage buffer ............................................................................................. 27 2.2 Strains used in this study .............................................................................................. 27 iv 2.3 Collection of water samples and bacterial enrichment ............................................... 27 2.4 Isolation of extended spectrum beta lactamase producing bacteria ........................ 28 2.5 Identification and characterization of ESBL producing bacteria using microbiological techniques ................................................................................................................................... 29 2.5.1 Antimicrobial susceptibility test ............................................................................ 29 2.5.2 ESBL and AmpC production .................................................................................. 30 2.5.3 Identification of isolated ESBL producing bacteria using API 20 E strip test .. 31 2.5.4 Biolog GEN III extended Biochemical test ............................................................ 32 2.5.5 Growth of isolated bacteria at different temperatures ........................................ 32 2.6 Identification and characterization of ESBL producing bacteria using molecular biology techniques ..................................................................................................................... 32 2.6.1 Purification of Genomic DNA ................................................................................. 32 2.6.2 Purification of Plasmid DNA .................................................................................. 33 2.6.3 Multiplex PCR Amplification of TEM, CTX and SHV genes ................................ 33 2.6.4 Multiplex PCR Amplification of OXA group genes .............................................. 34 2.6.5 PCR amplification of the 16S rRNA gene ............................................................
Load more

Recommended publications
  • Entwicklung Einer Software Zur Identifizierung Neuartiger Und
    Entwicklung einer Software zur Identifizierung neuartiger und bekannter Infektionserreger in klinischen Proben Dissertation zur Erlangung des Doktorgrades an der Fakult¨at fur¨ Mathematik, Informatik und Naturwissenschaften Fachbereich Biologie der Universit¨at Hamburg vorgelegt von Malik Alawi Hamburg, 2020 Vorsitzender der Prufungskommission¨ Dr. PD Andreas Pommerening-R¨oser Gutachter Professor Dr. Adam Grundhoff Professor Dr. Stefan Kurtz Datum der Disputation 30. April 2021 Abstract Sequencing of diagnostic samples is widely considered a key technology that may fun- damentally improve infectious disease diagnostics. The approach can not only identify pathogens already known to cause a specific disease, but may also detect pathogens that have not been previously attributed to this disease, as well as completely new, previously unknown pathogens. Therefore, it may significantly increase the level of preparedness for future outbreaks of emerging pathogens. This study describes the development and application of methods for the identification of pathogenic agents in diagnostic samples. The methods have been successfully applied multiple times under clinical conditions. The corresponding results have been published within the scope of this thesis. Finally, the methods were made available to the scientific community as an open source bioinformatics tool. The novel software was validated by conventional diagnostic methods and it was compared to established analysis pipelines using authentic clinical samples. It is able to identify pathogens from different diagnostic entities and often classifies viral agents down to strain level. Furthermore, the method is capable of assembling complete viral genomes, even from samples containing multiple closely related viral strains of the same viral family. In addition to an improved method for taxonomic classification, the software offers functionality which is not present in established analysis pipelines.
    [Show full text]
  • Pluralibacter Gergoviae Als Spender- Oder Empfängerorganismus Gemäß § 5 Absatz 1 Gentsv
    Az. 45241.0205 Juni 2020 Empfehlung der ZKBS zur Risikobewertung von Pluralibacter gergoviae als Spender- oder Empfängerorganismus gemäß § 5 Absatz 1 GenTSV Allgemeines Pluralibacter gergoviae (früher: Enterobacter gergoviae [1]) ist ein Gram-negatives, fakultativ anaerobes, peritrich begeißeltes, stäbchenförmiges Bakterium aus der Familie der Enterobacteriaceae, das zuerst 1980 beschrieben wurde [2]. Es ist weltweit verbreitet und wurde aus klinischen Proben (Blut, Urin, Sputum, Stuhl, Hautabstriche, Ohrendrainage, nicht näher beschriebene Wunden, Abszesse, Lunge, Niere) sowie aus dem Darm eines Roten Baumwollkapselwurms, Wasserproben und Kosmetikprodukten isoliert [2–7]. Das Überleben in Kosmetikprodukten wird dadurch ermöglicht, dass P. gergoviae eine hohe Toleranz gegen Konservierungsmittel wie Benzoesäure und Parabenen aufweist [8]. Aufgrund dieser Toleranz ist P. gergoviae in der Vergangenheit mehrfach als mikrobielle Verunreinigung in Kosmetikprodukten aufgetreten, die daraufhin zurückgerufen werden mussten [9]. Im klinischen Kontext tritt P. gergoviae vergleichsweise selten als Krankheitserreger auf. Das Bakterium löst vor allem bei Immunkompromittierten Infektionen aus, die tödlich verlaufen können. Es verursachte Harnwegsinfektionen oder Infektionen der Operationswunde bei Empfängern von Nierentransplantaten [10], mehrere Sepsisfälle auf einer Neugeborenenstation, von denen die Mehrzahl Frühgeborene betrafen [3], und führte zu einem Septischen Schock bei einem Leukämie-Patienten [11]. Bei Immunkompetenten wurden eine Sepsis
    [Show full text]
  • Annual Conference Abstracts
    ANNUAL CONFERENCE 14-17 April 2014 Arena and Convention Centre, Liverpool ABSTRACTS SGM ANNUAL CONFERENCE APRIL 2014 ABSTRACTS (LI00Mo1210) – SGM Prize Medal Lecture (LI00Tu1210) – Marjory Stephenson Climate Change, Oceans, and Infectious Disease Prize Lecture Dr. Rita R. Colwell Understanding the basis of antibiotic resistance University of Maryland, College Park, MD, USA as a platform for early drug discovery During the mid-1980s, satellite sensors were developed to monitor Laura JV Piddock land and oceans for purposes of understanding climate, weather, School of Immunity & Infection and Institute of Microbiology and and vegetation distribution and seasonal variations. Subsequently Infection, University of Birmingham, UK inter-relationships of the environment and infectious diseases Antibiotic resistant bacteria are one of the greatest threats to human were investigated, both qualitatively and quantitatively, with health. Resistance can be mediated by numerous mechanisms documentation of the seasonality of diseases, notably malaria including mutations conferring changes to the genes encoding the and cholera by epidemiologists. The new research revealed a very target proteins as well as RND efflux pumps, which confer innate close interaction of the environment and many other infectious multi-drug resistance (MDR) to bacteria. The production of efflux diseases. With satellite sensors, these relationships were pumps can be increased, usually due to mutations in regulatory quantified and comparatively analyzed. More recent studies of genes, and this confers resistance to antibiotics that are often used epidemic diseases have provided models, both retrospective and to treat infections by Gram negative bacteria. RND MDR efflux prospective, for understanding and predicting disease epidemics, systems not only confer antibiotic resistance, but altered expression notably vector borne diseases.
    [Show full text]
  • CATALOGO GENERALE - Listino Prezzi 2020 2021 Chromart CATALOGOTERRENI GENERALE Listinocromogeni Prezzi 2021 - 2022 Per La Microbiologia Industriale
    Microbiologia Microbiologia Microbiologia Microbiologia Microbiologia Microbiologia CATALOGO GENERALE - Listino Prezzi 2020 2021 CATALOGO ChromArt CATALOGOTERRENI GENERALE ListinoCROMOGENI Prezzi 2021 - 2022 Per la Microbiologia Industriale Microbiologia Clinica e Industriale Ph: A. Geraci Microbiologia Clinica e Industriale Terreni cromogeni Rev. 02/2021 per l’isolamento e l’identificazione dei principali patogeni ed indicatori fecali negli alimenti, mangimi ed acque. Biolife Biolife ItalianaBiolife srl - VItalianaiale Monza srl - 272Viale 20128 Monza Milano272 20128 - Tel. 02Milano 25209.1 - Tel. 02- www 25209.1.biolifeitaliana.i - www.biolifeitaliana.it t Biolife Italiana srl - Viale Monza 272 20128 Milano - Tel. 02 25209.1 - www.biolifeitaliana.it t .biolifeitaliana.i www - 25209.1 02 l. Te - Milano 20128 272 Monza iale V - l sr Italiana Biolife CONDIZIONI GENERALI DI VENDITA PREZZI I prezzi segnati nei nostri listini si intendono Iva esclusa e sono comprensivi di imballo normale e spedizione con vettori con noi convenzionati. Gli imballi speciali e/o refrigerati saranno addebitati al costo. Le spedizioni con vettori scelti dal cliente saranno a carico di quest’ultimo. L’IVA (Imposta sul Valore Aggiunto) è sempre a carico del Committente nella misura di legge. ORDINI Gli ordini devono essere formulati per iscritto e verranno evasi rispettando le unità di confezioni indicate nel listino. Per evitare errori raccomandiamo di indicare sempre negli ordini il numero di codice e la denominazione di ciascun articolo nonché la quantità richiesta. È nostro diritto accettare, annullare e procrastinare in tutto o in parte ordini a seguito di sopravvenute impossibilità da parte nostra, dei nostri fornitori e dei vettori. Tali cause ci sollevano da ogni obbligo precedentemente assunto con l’accettazione dell’ordine.
    [Show full text]
  • 2021 ECCMID | 00656 in Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales
    IHMA In Vitro Activities of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and 2122 Palmer Drive 00656 Schaumburg, IL 60173 USA Pseudomonas aeruginosa from Israel Collected Through the ATLAS Global Surveillance Program 2013-2019 www.ihma.com M. Hackel1, M. Wise1, G. Stone2, D. Sahm1 1IHMA, Inc., Schaumburg IL, USA, 2Pfizer Inc., Groton, CT USA Introduction Results Results Summary Avibactam (AVI) is a non-β- Table 1 Distribution of 2,956 Enterobacterales from Israel by species Table 2. In vitro activity of ceftazidime-avibactam and comparators agents Figure 2. Ceftazidime and ceftazidime-avibactam MIC distribution against 29 . Ceftazidime-avibactam exhibited a potent lactam, β-lactamase inhibitor against Enterobacterales and P. aeruginosa from Israel, 2013-2019 non-MBL carbapenem-nonsusceptible (CRE) Enterobacterales from Israel, antimicrobial activity higher than all Organism N % of Total mg/L that can restore the activity of Organism Group (N) %S 2013-2019 comparator agents against all Citrobacter amalonaticus 2 0.1% MIC90 MIC50 Range ceftazidime (CAZ) against Enterobacterales (2956) 20 Enterobacterales from Israel (MIC90, 0.5 Citrobacter braakii 5 0.2% Ceftazidime-avibactam 99.8 0.5 0.12 ≤0.015 - > 128 Ceftazidime Ceftazidime-avibactam organisms that possess Class 18 mg/L; 99.8% susceptible). Citrobacter freundii 96 3.2% Ceftazidime 70.1 64 0.25 ≤0.015 - > 128 A, C, and some Class D β- Cefepime 71.8 > 16 ≤0.12 ≤0.12 - > 16 16 . Susceptibility to ceftazidime-avibactam lactmase enzymes. This study Citrobacter gillenii 1 <0.1% Meropenem 98.8 0.12 ≤0.06 ≤0.06 - > 8 increased to 100% for the Enterobacterales Amikacin 95.4 8 2 ≤0.25 - > 32 14 examined the in vitro activity Citrobacter koseri 123 4.2% when MBL-positive isolates were removed Colistin (n=2544)* 82.2 > 8 0.5 ≤0.06 - > 8 12 of CAZ-AVI and comparators Citrobacter murliniae 1 <0.1% Piperacillin-tazobactam 80.4 32 2 ≤0.12 - > 64 from analysis.
    [Show full text]
  • 2016 Joint Meeting Program
    April 15 – 17, 2016 Fairmont Chicago Millennium Park • Chicago, Illinois The AAP/ASCI/APSA conference is jointly provided by Boston University School of Medicine and AAP/ASCI/APSA. Meeting Program and Abstracts www.jointmeeting.org www.jointmeeting.org Special Events at the 2016 AAP/ASCI/APSA Joint Meeting Friday, April 15 Saturday, April 16 ASCI President’s Reception ASCI Food and Science Evening 6:15 – 7:15 p.m. 6:30 – 9:00 p.m. Gold Room The Mid-America Club, Aon Center ASCI Dinner & New Member AAP Member Banquet Induction Ceremony (Ticketed guests only) (Ticketed guests only) 7:00 – 10:00 p.m. 7:30 – 9:45 p.m. Imperial Ballroom, Level B2 Rouge, Lobby Level How to Solve a Scientific Puzzle: Speaker: Clara D. Bloomfield, MD Clues from Stockholm and Broadway The Ohio State University Comprehensive Cancer Center Speaker: Joe Goldstein, MD APSA Welcome Reception & University of Texas Southwestern Medical Center at Dallas Presidential Address APSA Dinner (Ticketed guests only) 9:00 p.m. – Midnight Signature Room, 360 Chicago, 7:30 – 9:00 p.m. John Hancock Center (off-site) Rouge, Lobby Level Speaker: Daniel DelloStritto, APSA President Finding One’s Scientific Niche: Musings from a Clinical Neuroscientist Speaker: Helen Mayberg, MD, Emory University Dessert Reception (open to all attendees) 10:00 p.m. – Midnight Imperial Foyer, Level B2 Sunday, April 17 APSA Future of Medicine and www.jointmeeting.org Residency Luncheon Noon – 2:00 p.m. Rouge, Lobby Level 2 www.jointmeeting.org Program Contents General Program Information 4 Continuing Medical Education Information 5 Faculty and Speaker Disclosures 7 Scientific Program Schedule 9 Speaker Biographies 16 Call for Nominations: 2017 Harrington Prize for Innovation in Medicine 26 AAP/ASCI/APSA Joint Meeting Faculty 27 Award Recipients 29 Call for Nominations: 2017 Harrington Scholar-Innovator Award 31 Call for Nominations: George M.
    [Show full text]
  • On the Stability of Sequences Inserted Into Viral Genomes Anouk Willemsen1,*,† and Mark P
    Virus Evolution, 2019, 5(2): vez045 doi: 10.1093/ve/vez045 Review article On the stability of sequences inserted into viral genomes Anouk Willemsen1,*,† and Mark P. Zwart2,*,‡ 1Laboratory MIVEGEC (UMR CNRS IRD University of Montpellier), Centre National de la Recherche Scientifique (CNRS), 911 Avenue Agropolis, BP 64501, 34394 Montpellier cedex 5, France and 2Netherlands Institute of Ecology (NIOO-KNAW), Postbus 50, 6700 AB, Wageningen, The Netherlands *Corresponding author: E-mail: [email protected]; [email protected] †http://orcid.org/0000-0002-8511-3244 ‡http://orcid.org/0000-0003-4361-7636 Abstract Viruses are widely used as vectors for heterologous gene expression in cultured cells or natural hosts, and therefore a large num- ber of viruses with exogenous sequences inserted into their genomes have been engineered. Many of these engineered viruses are viable and express heterologous proteins at high levels, but the inserted sequences often prove to be unstable over time and are rapidly lost, limiting heterologous protein expression. Although virologists are aware that inserted sequences can be unstable, processes leading to insert instability are rarely considered from an evolutionary perspective. Here, we review experimental work on the stability of inserted sequences over a broad range of viruses, and we present some theoretical considerations concerning insert stability. Different virus genome organizations strongly impact insert stability, and factors such as the position of insertion can have a strong effect. In addition, we argue that insert stability not only depends on the characteristics of a particular genome, but that it will also depend on the host environment and the demography of a virus population.
    [Show full text]
  • In Vitro Activities of Aztreonam-Avibactam and Ceftazidime-Avibactam Against Less Commonly Encountered Gram-Negative Bacteria Co
    IHMA, Inc. In Vitro Activities of Aztreonam-avibactam and Ceftazidime-avibactam Against Less Commonly Encountered Gram-Negative 2122 Palmer Drive P1155 Schaumburg, IL 60173 USA Bacteria Collected During the ATLAS Global Surveillance Program 2012-2017 www.ihma.com M. Hackel1, G Stone2, B. deJonge3, D. Sahm1 1IHMA, Inc., Schaumburg IL, USA 2Pfizer Inc., Cambridge, MA USA 3Pfizer Inc., Cambridge MA, USA Introduction Results Results While antimicrobial susceptibility Table 1. Less commonly isolated gram-negative species Table 2. In vitro activity of ceftazidime-avibactam, aztreonam-avibactam and comparators against less commonly encountered gram-negative bacteria collected in 2012-2017 . ATM-AVI and CAZ-AVI showed MIC90 values from the ATLAS Global Surveillance Program 2012-2017 AZT-AVI CAZ-AVI CST* MEM TGC TZP LVX profiles have been well described in Organism N ranging from ≤0.015 to 0.5 mg/L and 0.06 to 1 %S MIC Range %S MIC Range %S MIC Range %S MIC Range %S MIC Range %S MIC Range %S MIC Range more common members of the 90 90 90 90 90 90 90 mg/L, respectively, against members of the Organism N Percent of total Acinetobacter nosocomialis 183 na 64 2 - >128 na 32 1 - >128 96.8 2 0.25 - >8 79.8 > 8 0.015 - >8 na 1 0.06 - 4 na > 128 ≤0.25 - >128 76.5 >4 0.06 - >8 Enterobacterales, notably Escherichia Enterobacterales (Table 2). 98.3% were coli and Klebsiella pneumoniae, and in Acinetobacter nosocomialis 183 5.1 Acinetobacter pittii 402 na 64 2 - >128 na 16 0.5 - >128 99.2 2 0.12 - 4 92.3 1 ≤0.06 - >8 na 1 0.03 - >8 na 64 ≤0.25 - >128 88.6 2 0.06 - >8 Citrobacter spp.
    [Show full text]
  • George Michael Humphrey Birchenough
    GEORGE MICHAEL HUMPHREY BIRCHENOUGH Analysis of intestinal factors contributing to the age- dependency of systemic neuropathogenic Escherichia coli K1 infection in the neonatal rat Thesis submitted in accordance with the requirements of the UCL School of Pharmacy for the degree of Doctor of Philosophy Microbiology Group, Department of Pharmaceutics, UCL School of Pharmacy July 2012 PLAGIARISM STATEMENT This thesis describes research conducted in the UCL School of Pharmacy between October 2008 and July 2012 under the supervision of Professor Peter W. Taylor. I certify that the research described is original and that any parts of the work that have been conducted by collaboration are clearly indicated. I also certify that I have written all the text herein and have clearly indicated by suitable citation any part of the dissertation that has already appeared in publication. Signature: Date: Acknowledgements Firstly I wish to thank my supervisor, Professor Peter Taylor, for giving me the opportunity to work on such an interesting and rewarding project. Your continued support and enthusiasm has been a constant source of encouragement and I greatly appreciate all the advice and help (both scientific and general!) that you have provided over the last four years. I owe you a lot of beer. I also wish to thank my amazing parents for all their love and support over the eight years of my higher education. Without your enthusiasm and belief I would not have been able to follow this path. I sincerely promise I will now get a job! Furthermore, I wish to thank colleagues at the London School of Hygiene & Tropical Medicine, Dr.
    [Show full text]
  • A Major-Capsid-Protein-Based Multiplex PCR Assay for Rapid
    Archives of Virology (2019) 164:819–830 https://doi.org/10.1007/s00705-019-04148-6 ORIGINAL ARTICLE A major‑capsid‑protein‑based multiplex PCR assay for rapid identifcation of selected virulent bacteriophage types Yannick Born1 · Leandra E. Knecht1,2 · Mirjam Eigenmann1 · Michel Bolliger1 · Jochen Klumpp2 · Lars Fieseler1 Received: 27 September 2018 / Accepted: 14 December 2018 / Published online: 23 January 2019 © The Author(s) 2019 Abstract Bacteriophages represent a promising alternative for controlling pathogenic bacteria. They are ubiquitous in the environment, and their isolation is usually simple and fast. However, not every phage is suitable for biocontrol applications. It must be virulent (i.e., strictly lytic), non-transducing, and safe. We have developed a method for identifying selected types of virulent phages at an early stage of the isolation process to simplify the search for suitable candidates. Using the major capsid pro- tein (MCP) as a phylogenetic marker, we designed degenerate primers for the identifcation of Felix O1-, GJ1-, N4-, SP6-, T4-, T7-, and Vi1-like phages in multiplex PCR setups with single phage plaques as templates. Performance of the MCP PCR assay was evaluated with a set of 26 well-characterized phages. Neither false-positive nor false-negative results were obtained. In addition, 154 phages from enrichment cultures from various environmental samples were subjected to MCP PCR analysis. Eight of them, specifc for Salmonella enterica, Escherichia coli, or Erwinia amylovora, belonged to one of the selected phage types. Their PCR-based identifcation was successfully confrmed by pulsed-feld gel electrophoresis of the phage genomes, electron microscopy, and sequencing of the amplifed mcp gene fragment.
    [Show full text]
  • International Journal of Systematic and Evolutionary Microbiology (2016), 66, 5575–5599 DOI 10.1099/Ijsem.0.001485
    International Journal of Systematic and Evolutionary Microbiology (2016), 66, 5575–5599 DOI 10.1099/ijsem.0.001485 Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. Mobolaji Adeolu,† Seema Alnajar,† Sohail Naushad and Radhey S. Gupta Correspondence Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Radhey S. Gupta L8N 3Z5, Canada [email protected] Understanding of the phylogeny and interrelationships of the genera within the order ‘Enterobacteriales’ has proven difficult using the 16S rRNA gene and other single-gene or limited multi-gene approaches. In this work, we have completed comprehensive comparative genomic analyses of the members of the order ‘Enterobacteriales’ which includes phylogenetic reconstructions based on 1548 core proteins, 53 ribosomal proteins and four multilocus sequence analysis proteins, as well as examining the overall genome similarity amongst the members of this order. The results of these analyses all support the existence of seven distinct monophyletic groups of genera within the order ‘Enterobacteriales’. In parallel, our analyses of protein sequences from the ‘Enterobacteriales’ genomes have identified numerous molecular characteristics in the forms of conserved signature insertions/deletions, which are specifically shared by the members of the identified clades and independently support their monophyly and distinctness. Many of these groupings, either in part or in whole, have been recognized in previous evolutionary studies, but have not been consistently resolved as monophyletic entities in 16S rRNA gene trees. The work presented here represents the first comprehensive, genome- scale taxonomic analysis of the entirety of the order ‘Enterobacteriales’.
    [Show full text]
  • The Landscape of Viral Associations in Human Cancers Marc Zapatka1*, Ivan Borozan2*, Daniel S
    bioRxiv preprint doi: https://doi.org/10.1101/465757; this version posted September 9, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The landscape of viral associations in human cancers Marc Zapatka1*, Ivan Borozan2*, Daniel S. Brewer4,5*, Murat Iskar1*, Adam Grundhoff6, Malik Alawi6,7, Nikita Desai8,9, Holger Sültmann10,16, Holger Moch11, PCAWG Pathogens Working Group, ICGC/TCGA Pan-cancer Analysis of Whole Genomes Network, Colin S. Cooper3,4, Roland Eils12,13, Vincent Ferretti14,15, Peter Lichter1,16 1 Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany. 2 Informatics and Bio-computing Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada 3 The Institute of Cancer Research, London, UK. 4 Norwich Medical School, University of East Anglia, Norwich, UK 5 Earlham Institute, Norwich, UK. 6 Virus Genomics, Heinrich-Pette-Institute, Hamburg, Germany 7 Bioinformatics Core, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 8 Division of Cancer Studies, King's College London, London, UK 9 Cancer Systems Biology Laboratory, The Francis Crick Institute, London, UK 10 Cancer Genome Research, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany 11 Department of Pathology and Molecular Pathology, University and University Hospital Zürich, Zürich, Switzerland 12 Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany. 13 Department of Bioinformatics and Functional Genomics, Institute of Pharmacy and Molecular Biotechnology, Heidelberg University and BioQuant Center, Heidelberg, Germany 14 Ontario Institute for Cancer Research, MaRS Centre, Toronto, Canada 15 Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, Canada.
    [Show full text]